Aegis Capital Corp. Acted as Sole Bookrunner on a $4.1 Million Underwritten Public Offering of Ordinary Shares, Inclusive of the Over-Allotment, for China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC).
China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) successfully completed a $4.1 million underwritten public offering of ordinary shares, including the over-allotment. Aegis Capital Corp. acted as the sole bookrunner for this offering. Founded in 2005 and headquartered in Jiangsu Province, China, the company specializes in the research and development of traditional Chinese medicine pieces, facilitating their marketing and sales to the market. The funds raised are expected to support further growth initiatives.
- Successfully raised $4.1 million through public offering.
- Funds will support growth initiatives.
- Potential shareholder dilution due to the issuance of new shares.
NEW YORK, NY / ACCESSWIRE / January 20, 2022 / Aegis Capital Corp. acted as Sole Bookrunner on a
About China SXT Pharmaceuticals, Inc.
Founded in 2005 and headquartered in Taizhou City, Jiangsu Province, China, China SXT Pharmaceuticals, Inc. is an innovative pharmaceutical company focusing on the research, development, manufacture, marketing and sales of traditional Chinese medicine pieces, which is a type of Traditional Chinese Medicine that has been processed to be ready for use.
For more information, please visit www.sxtchina.com
About Aegis Capital Corporation
Aegis Capital Corporation ("Aegis") has been in the wealth management and investment banking business since 1984. Aegis is dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. Aegis also provides research and sales and trading services to institutional investors. Aegis offers its investment representatives a conflict free service platform and is able to provide a full-range of products and services including investment banking, wealth management, insurance, retirement planning, structured products, private equity, alternatives, equity research, fixed income and special purpose vehicles.
For more information about this offering or Investment Banking Services please email Banking@aegiscap.com or call (212) 813-1010.
Brokerage and investment advisory services are offered through Aegis Capital Corporation, a member of FINRA and SIPC. Investment and insurance products offered are not insured by the FDIC or any other federal government agency, are not deposits or other obligations of, or guaranteed by, a bank or any bank affiliate, and are subject to investment risks, including possible loss of the principal amount invested.
SOURCE: Aegis Capital Corp.
View source version on accesswire.com:
https://www.accesswire.com/684835/Aegis-Capital-Corp-Acted-as-Sole-Bookrunner-on-a-41-Million-Underwritten-Public-Offering-of-Ordinary-Shares-Inclusive-of-the-Over-Allotment-for-China-SXT-Pharmaceuticals-Inc-NASDAQ-SXTC
FAQ
What was the amount raised in China SXT Pharmaceuticals' public offering?
Who acted as the bookrunner for the SXTC public offering?
How does the public offering impact shareholders of SXTC?
What is the focus of China SXT Pharmaceuticals?
